BCL2 and B-cell chronic lymphocytic leukemia: There are now several selective BCL-2 antagonists targeting anti-apoptotic BCL-2 family proteins, with the selective BCL-2 antagonist ABT-199 (venetoclax) now approved for the treatment of acute myeloid leukaemia, chronic and small lymphocytic lymphoma patients who received at least one prior therapy [5].